BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8817396)

  • 1. The significance of microbial cultures of the hematopoietic support for patients receiving high-dose chemotherapy.
    Cohen A; Tepperberg M; Waters-Pick B; Coniglio D; Perfect J; Peters WP; Gilbert C; Morgan C; Vredenburgh JJ
    J Hematother; 1996 Jun; 5(3):289-94. PubMed ID: 8817396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
    Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
    J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer.
    Ho AD; Glück S; Germond C; Sinoff C; Dietz G; Maruyama M; Corringham RE
    Leukemia; 1993 Nov; 7(11):1738-46. PubMed ID: 7901454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
    Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
    Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contamination of bone marrow products with an actinomycete resembling Microbacterium species and reinfusion into autologous stem cell and bone marrow transplant recipients.
    Hirji Z; Saragosa R; Dedier H; Crump M; Franke N; Burrows L; Jamieson F; Brown S; Gardam MA
    Clin Infect Dis; 2003 May; 36(10):e115-21. PubMed ID: 12746790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colony-stimulating factor mobilized stem cells.
    Krüger W; Kröger N; Tögel F; Badbaran A; Renges H; Gieseking F; Gutensohn K; Jänicke F; Zander AR
    J Hematother Stem Cell Res; 2001 Apr; 10(2):303-7. PubMed ID: 11359677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of cancer cells in peripheral blood stem cells of women with breast cancer by RT-PCR and cell culture.
    Krüger WH; Stockschläder M; Hennings S; Aschenbrenner M; Gruber M; Gutensohn K; Löliger C; Gieseking F; Jonat W; Zander AR
    Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S18-20. PubMed ID: 8899163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor.
    Kohno A; Takeyama K; Narabayashi M; Okamoto R; Adachi I; Tobinai K; Shimoyama M
    Bone Marrow Transplant; 1995 Jan; 15(1):49-54. PubMed ID: 7538002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
    Vredenburgh JJ; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros WP; Peters WP; Bast RC
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):91-7. PubMed ID: 9267669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide mobilization of peripheral blood stem cells for use in autologous transplantation after high-dose chemotherapy: clinical results in patients with contaminated or hypocellular bone marrow.
    Myers SE; Williams SF; Geller RB
    J Hematother; 1992; 1(1):27-33. PubMed ID: 1365014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbial contamination of harvested bone marrow and peripheral blood.
    Prince HM; Page SR; Keating A; Saragosa RF; Vukovic NM; Imrie KR; Crump M; Stewart AK
    Bone Marrow Transplant; 1995 Jan; 15(1):87-91. PubMed ID: 7742761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
    Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
    J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful collection and transplantation of peripheral blood stem cells in cancer patients using large-volume leukaphereses.
    Murea S; Goldschmidt H; Hahn U; Pförsich M; Moos M; Haas R
    J Clin Apher; 1996; 11(4):185-94. PubMed ID: 8986864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer.
    Peters WP; Ross M; Vredenburgh JJ; Hussein A; Rubin P; Dukelow K; Cavanaugh C; Beauvais R; Kasprzak S
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):25-31. PubMed ID: 7916487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of epirubicin/paclitaxel combination in mobilizing large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen.
    Zibera C; Pedrazzoli P; Ponchio L; Gibelli N; Lanza A; Da Prada GA; Zambelli A; Perotti C; Torretta L; Salvaneschi L; Robustelli della Cuna G
    Haematologica; 1999 Oct; 84(10):924-9. PubMed ID: 10509041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.
    Glück S; Ross AA; Layton TJ; Ostrander AB; Goldstein LC; Porter K; Ho AD
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):316-23. PubMed ID: 9502299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emergence of peripheral blood progenitor cells to support intensive chemotherapy for patients with breast cancer.
    Demetri GD
    Pharmacotherapy; 1996; 16(3 Pt 2):94S-100S. PubMed ID: 8726588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbial contamination of peripheral blood stem cell collections.
    Attarian H; Bensinger WI; Buckner CD; McDonald DL; Rowley SD
    Bone Marrow Transplant; 1996 May; 17(5):699-702. PubMed ID: 8733684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I; Cepulić BG; Mazić S
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.